Principal Financial Group Inc. Reduces Holdings in Evolus, Inc. (NASDAQ:EOLS)

Principal Financial Group Inc. reduced its holdings in shares of Evolus, Inc. (NASDAQ:EOLS) by 8.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,381 shares of the company’s stock after selling 2,793 shares during the period. Principal Financial Group Inc.’s holdings in Evolus were worth $492,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Assenagon Asset Management S.A. lifted its position in shares of Evolus by 5,627.2% in the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after acquiring an additional 930,566 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Evolus by 24.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock valued at $1,965,000 after purchasing an additional 35,760 shares during the period. Armistice Capital LLC purchased a new position in Evolus in the 2nd quarter worth approximately $3,906,000. California State Teachers Retirement System boosted its stake in Evolus by 1.6% in the 1st quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock worth $674,000 after purchasing an additional 739 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Evolus by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock valued at $559,000 after buying an additional 1,637 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EOLS. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, November 7th. Barclays increased their price objective on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Friday, September 13th.

Evolus Price Performance

Shares of EOLS stock opened at $12.60 on Monday. The firm has a market capitalization of $797.83 million, a price-to-earnings ratio of -13.85 and a beta of 1.31. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The stock’s 50-day simple moving average is $15.59 and its 200-day simple moving average is $13.87. Evolus, Inc. has a fifty-two week low of $9.29 and a fifty-two week high of $17.82.

Insiders Place Their Bets

In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The trade was a 6.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. This represents a 2.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.